Virginie Monteilhet

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

Sylvie Boutin, Virginie Monteilhet, P. Véron et al. · Human Gene Therapy · 2010 · 922 citations

Vaccination, Molecular Virology, Allergy +12

A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8

Virginie Monteilhet, Samir Saheb, Sylvie Boutin et al. · Molecular Therapy · 2011 · 193 citations · Full text

Humoral and Cellular Capsid-Specific Immune Responses to Adeno-Associated Virus Type 1 in Randomized Healthy Donors

P. Véron, Christian Leborgne, Virginie Monteilhet et al. · The Journal of Immunology · 2012 · 79 citations

Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide

David‐Alexandre Gross, Christian Leborgne, Pascal Chappert et al. · Scientific Reports · 2019 · 20 citations · Full text

Simple conditioning with monospecific CD4+CD25+ regulatory T cells for bone marrow engraftment and tolerance to multiple gene products

David‐Alexandre Gross, Pascal Chappert, Marylène Leboeuf et al. · Blood · 2006 · 12 citations